Microcap Ledger Entrada Therapeutics, Inc. $TRDA
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Global Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- Boston, MA
- Fiscal year end
- December 31
- Shares outstanding
- 38,936,669 [10-Q 2026-08-05]
What the company doesAI summary of filing
Entrada Therapeutics is a clinical-stage biopharmaceutical company developing genetic medicines based on its proprietary Endosomal Escape Vehicle (EEV) platform to treat neuromuscular and inherited retinal diseases. The company is advancing multiple clinical-stage programs, including four DMD exon-skipping candidates (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51), a partnered DM1 candidate (VX-670 with Vertex Pharmaceuticals), and an ocular candidate for Usher syndrome (ENTR-801). Entrada does not currently generate product revenue and is pre-revenue, relying on research funding and milestone payments from its collaboration with Vertex, from which it has received $342.5 million to date. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $1.77M | −$82.48M | −$74.16M | $99.28M | [10-Q 2026-08-05] |
| FY ended Dec 2025 | $25.42M | −$143.75M | −$128.51M | $90.39M | [10-K 2026-02-26] |
| FY ended Dec 2024 | $210.78M | $65.63M | −$41.56M | $101.21M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$37.08M
- Cash runway Estimate
- ~8 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-10-31 | 37,419,975 | [10-Q 2024-11-05] |
| 2025-02-20 | 37,594,630 | [10-K 2025-02-27] |
| 2025-04-30 | 37,953,417 | [10-Q 2025-05-08] |
| 2025-07-31 | 38,037,079 | [10-Q 2025-08-06] |
| 2025-10-31 | 38,219,232 | [10-Q 2025-11-06] |
| 2026-02-19 | 38,284,313 | [10-K 2026-02-26] |
| 2026-04-30 | 38,820,616 | [10-Q 2026-05-07] |
| 2026-07-31 | 38,936,669 | [10-Q 2026-08-05] |
- Shelf registration
- S-3 filed 2025-11-06; declared effective 2025-12-03 [S-3 2025-11-06]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-09-09 | Mpm Bioventures 2018, L.P. | sell | 28,837 | $7.13 | [4 2026-09-09] |
| 2026-09-09 | Mpm Bioventures 2014, L.P. | sell | 28,837 | $7.13 | [4 2026-09-09] |
| 2026-09-08 | Mpm Bioventures 2018, L.P. | sell | 192,500 | $7.41 | [4 2026-09-09] |
| 2026-09-08 | Mpm Bioventures 2014, L.P. | sell | 192,500 | $7.41 | [4 2026-09-09] |
| 2026-09-04 | Mpm Bioventures 2018, L.P. | sell | 38,500 | $7.11 | [4 2026-09-09] |
| 2026-09-04 | Mpm Bioventures 2014, L.P. | sell | 38,500 | $7.11 | [4 2026-09-09] |
| 2026-09-03 | Mpm Bioventures 2018, L.P. | sell | 32,263 | $7.17 | [4 2026-09-03] |
| 2026-09-03 | Mpm Bioventures 2014, L.P. | sell | 32,263 | $7.17 | [4 2026-09-03] |
| 2026-09-02 | Mpm Bioventures 2018, L.P. | sell | 25,131 | $7.19 | [4 2026-09-03] |
| 2026-09-02 | Mpm Bioventures 2014, L.P. | sell | 25,131 | $7.19 | [4 2026-09-03] |
| 2026-09-02 | Doshi Dipal | other | 8,724 | $7.14 | [4 2026-09-03] |
| 2026-09-02 | Dowden Nathan J | other | 2,528 | $7.14 | [4 2026-09-03] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-10 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-05 | 10-Q | Quarterly report |
| 2026-08-05 | 8-K | Results of operations |
| 2026-06-10 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-19 | 8-K | Regulation FD disclosure |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-05-07 | 8-K | Results of operations; Regulation FD disclosure |
| 2026-04-24 | DEF 14A | Proxy statement |
| 2026-02-26 | 10-K | Annual report |
| 2026-02-26 | 8-K | Results of operations |
| 2026-01-08 | 8-K | Results of operations; Regulation FD disclosure; Other events |
Alerts for $TRDA
Email me when Entrada Therapeutics, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.